RENOVORX INC. - COMMON STOCK

0.9980

31-October-24 15:58:46

15 minutes delayed

Stocks

-0.0020

-0.20%

Today's range

0.9000 - 1.0000

ISIN

N/A

Source

NASDAQ

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

25 Sep 2024 08:30:00 By Nasdaq GlobeNewswire
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

19 Sep 2024 08:30:00 By Nasdaq GlobeNewswire
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York

27 Aug 2024 08:30:00 By Nasdaq GlobeNewswire
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

14 Aug 2024 08:30:00 By Nasdaq GlobeNewswire
RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®

31 Jul 2024 08:30:00 By Nasdaq GlobeNewswire
RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

08 Jul 2024 08:30:00 By Nasdaq GlobeNewswire
University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial

26 Jun 2024 08:30:00 By Nasdaq GlobeNewswire
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

10 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

<<
<
1
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.